NextRNA Therapeutics

NextRNA Therapeutics develops small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) for disease treatment. It disrupts critical lncRNA-RBP interactions, central to pathology. Leveraging its proprietary NextMap™ platform, NextRNA integrates computational biology with deep lncRNA expertise and chemical capabilities, designing precision medicines.

Founded in 2021 by Dominique Verhelle, PhD, MBA, and co-founders, NextRNA Therapeutics recognized lncRNAs as an expansive, underexplored class of therapeutic targets. Insight into lncRNAs' role in recruiting RBPs drove the team, under Verhelle’s leadership, to unlock new treatments by inhibiting lncRNA function.

NextRNA targets high unmet needs in oncology and neuroscience, where lncRNA dysregulation contributes to disease. Its vision advanced pioneering science, offering a differentiated strategy to target lncRNA-RBP interactions for patient benefit. While operations conclude in August 2025, NextRNA's efforts inform future therapeutic exploration in this biological space.

High-Level Overview

NextRNA Therapeutics was a biotechnology company developing small molecule therapeutics targeting long non-coding RNAs (lncRNAs) to treat diseases in oncology and neuroscience. It served patients with serious conditions like cancer by addressing lncRNA-driven pathologies through a proprietary computational engine that identifies disease-relevant lncRNAs and disrupts their interactions with RNA-binding proteins[1][2][3][4][5][6]. The company raised $56.1 million in seed and Series A funding in 2022, collaborated with Bayer on a $500+ million oncology deal, and advanced early programs in oncology and immunology before ceasing operations in August 2025 due to market conditions[1][3][4][6].

Origin Story

NextRNA was founded in January 2021 (with some sources citing 2020) in Boston/Cambridge, Massachusetts, based on pioneering lncRNA research by Carl Novina, M.D., Ph.D., from Dana-Farber Cancer Institute, and Dominique Verhelle, Ph.D., MBA, who served as co-founder, chief scientific officer, and interim CEO[1][3][4][5][6]. The idea emerged from decoding lncRNA-protein interactions to create novel medicines, building on Novina's work to systematically identify and drug these targets for unmet needs in cancer and beyond[4]. Early traction included launching in March 2022 with $56 million in funding led by Cobro Ventures and Lightchain Capital, assembling a team, building a drug discovery engine, and advancing two small molecule programs[4].

Core Differentiators

• Proprietary Drug Discovery Engine: Computational platform to identify, validate, and target disease-relevant lncRNAs by developing small molecules that selectively disrupt lncRNA-RNA-binding protein interactions, enabling a pipeline across oncology, neuroscience, and immunology[1][2][4][5].
• Focus on Undruggable Targets: Specialized in lncRNAs, a vast "dark genome" class previously overlooked, positioning NextRNA as a leader in non-coding RNA-directed medicines[1][3][4].
• Strong Partnerships and Expertise: Collaborated with Bayer on oncology lncRNA targets (over $500 million potential); bolstered by scientific advisors like Novina and board additions like Lori Friedman, Ph.D., from ORIC Pharmaceuticals[1][6].
• Rapid Pipeline Progress: From founding to advancing lead programs in under two years, with plans for transformative therapies in multiple diseases[4].

Role in the Broader Tech Landscape

NextRNA rode the RNA therapeutics wave, targeting the "dark genome" of non-coding RNAs amid growing recognition of lncRNAs' role in cancer, neurodegeneration, and metabolic diseases—exemplified by parallel deals like Eli Lilly's $1 billion pact with HAYA Therapeutics[1]. Timing aligned with post-2020 biotech funding peaks and advances in computational biology, making lncRNA targeting feasible amid challenges in traditional protein-focused drugs[1][3][4]. Market forces like rising oncology needs and small molecule preference favored it, influencing the ecosystem by validating lncRNA platforms—paving the way for peers like Flamingo Therapeutics despite its closure[1][3].

Quick Take & Future Outlook

NextRNA's shutdown in August 2025 highlights biotech volatility, with its technology and collaborations likely absorbed by partners like Bayer or inspiring successors in lncRNA drugging[1][3]. Trends like AI-driven target discovery and precision RNA medicines will shape this space, potentially amplifying NextRNA's foundational contributions to oncology pipelines. Its legacy endures as a pioneer, proving lncRNAs' druggability even as operations end, fueling bolder bets on the non-coding genome.